^
    Back
    Association details:
    Biomarker:NRAS overexpression
    Cancer:Melanoma
    Drug:DEL-22379 (ERK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cancer Cell
    Title:

    Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes

    Excerpt:
    In agreement, we found that overexpression of NRASV12 in A375 cells made them refractory to the anti-proliferative effect of the BRAF inhibitor PLX-4032. Contrarily, these cells remained sensitive to inhibition by DEL-22379.
    DOI:
    https://doi.org/10.1016/j.ccell.2015.07.001